2,3-Dehydrosilybin is a better DNA topoisomerase I inhibitor than its parental silybin

Chemotherapy

Volumn 55, Issue 1, 2008, Pages 42-48

  Thongphasuk, Piyanut ^b   Stremmel, Wolfgang ^a   Chamulitrat, Walee ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b RANGSIT UNIVERSITY   (Thailand)

^c Forschungsgruppen   (Germany)

Author keywords

Apoptosis; Oxidized silybin; Sensitization mechanism; Topoisomerase I

Indexed keywords

2,3 DEHYDROSILYBIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; SILIBININ; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL FREE SYSTEM; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; DATA INTERPRETATION, STATISTICAL; DNA TOPOISOMERASES, TYPE I; HUMANS; SILYMARIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56349127020     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000175466     Document Type: Article

References (26)

1. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB: Anticancer potential of silymarin: from bench to bed side. Anticancer Res 2006;26:4457-4498.
2. Singh RP, Agarwal R: Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 2004;4:1-11.
3. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ: Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 2005;65:4448-4457.
4. Gazak R, Svobodova A, Psotova J, Sedmera P, Prikrylova V, Waterova D, Kren V: Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 2004;12:5677-5687.
5. Thongphasuk P, Stremmel W, Chamulitrat W: Potent direct or TNF-α-promoted anticancer effects of 2,3-dehydrosilybin: comparison study with silybin. Chemotherapy 2008;54:23-30.
6. Huber A, Thongphasuk P, Erben G, Lehmann WD, Tuma S, Stremmel W, Chamulitrat W: Significantly greater antioxidant anticancer activities of 2,3-dehydrosilybin than silybin. Biochim Biophys Acta 2008;1780:837-847.
7. Tyagi AK, Agarwal C, Chan DC, Agarwal R: Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 2004;11:493-499.
8. Dzubak P, Hajduch M, Gazak R, Svobodova A, Psotova J, Waltrovo D, Sedmera P, Kren V: New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg Med Chem 2006;14:3793-3810.
9. Bailly C: Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58.
10. Hentze H, Latta M, Kunnstle G, Dhakshinamoorthy S, Mg PY, Porter AG, Wendel A: Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis. Hepatology 2004;39:1311-1320.
11. Baloch Z, Cohen S, Coffman FD: Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. J Immunol 1990;145:2908-2913.
12. Boege F, Straub T, Kehr A, Boesenberg C, Christiansen K, Andersen A, Jakob F, Koehrle J: Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J Biol Chem 1996;271:2262-2270.
13. Web MR, Eberler SE: Comparative analysis of topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: structural determinates of activity. Biochem J 2004;384:527-541.
14. Sinha BK: Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995;49:11-19.
15. Chamulitrat W, Schmidt R, Chunglok W, Kohl A, Tomakidi P: Epithelium and fibroblast-like phenotypes derived from HPV16 E6/E7-immortalized human gingival keratinocytes following chronic ethanol treatment. Eur J Cell Biol 2003;82:313-322.
16. Habermeyer M, Fritz J, Barthelmes HU, Christensen MO, Larsen MK, Boege F, Marko D: Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity. Chem Res Toxicol 2005;18:1395-1404.
17. Belliard AM, Lacour B, Farinotti R, Leroy C: Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J Pharm Sci 2004;93:1524-1536.
18. Kluza J, Gallego MA, Loyens A, Beauvillain JC, Sousa-Faro JM, Cuevas C, Marchetti P, Bailly C: Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res 2006;66:3177-3187.
19. Shi RX, Ong CN, Shen HM: Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells. Oncogene 2004;23:7712-7721.
20. Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY, Jeong S: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 2003;63:621-626.
21. Das BB, Sen N, Roy A, Dasgupta SB, Ganguly A, Mohanta BC, Dinda B, Majumder HK: Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I. Nucleic Acids Res 2006;34:1121-1132.
22. Baloch Z, Cohen S, Fresa K, Coffman FD: Modulation of topoisomerase activities by tumor necrosis factor. Cell Immunol 1995;160:98-103
23. Austin CA, Patel S, Ono K, Nakane H, Fisher LM: Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J 1992;282:883-889.
24. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R: Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 1995;58:217-225.
25. Lim DS, Kwak YS, Lee KH, Ko SH, Yoon WH, Lee WY, Kim CH: Topoisomerase I inactivation by reticulol and its in vivo cytotoxicity against B16F10 melanoma. Chemotherapy 2003;49:257-263.
26. Griffith TS, Kemp TJ: The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother Pharmacol 2003;52:175-184.